Autopsy report · NCT01790295
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Cause of deathNo reason given
Life of this trial
- Registered 9 months before it started.
- Ran for about 3 years 11 months before it stopped.
- 21 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- John Mascarenhas
- Sponsor type
- University, hospital or other
- Conditions
- Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis
- Interventions
- Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
- Participants
- 21
- Sites
- 8
- Countries
- Canada, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.